Close
Solutions
Online Inquiry
Global Services

CAR Targeting Blastoma-specific Antigens

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Creative Biolabs has many years of experience in CARs construction for targeting Blastoma-specific antigens. We can provide highly customized and best-in-class CARs products according to our customers'special and strict requirements.

CAR Targeting Blastoma-specific Antigens From bionews texas news, © BioNews Services 2015.

Blastoma is a kind of cancer arising in embryonic tissue, which is more commonly diagnosed in children than in adults. According to the location of cancer cells, blastoma can be further classified in to several subtypes such as Medulloblastoma, Hepatoblastoma, Nephroblastoma, Pleuropulmonary blastoma, Retinoblastoma, Neuroblastoma and Osteoblastoma. The symptoms of blastoma are variable. Radiation therapy, surgery and sometimes adjuvant chemotherapy are employed to treat this kind of diseases. However, these traditional treatments may also cause late complications and long term side effects. Adoptive cell therapy targeting specific blastoma antigens has become a very promising therapy which can overcome the disadvantages of traditional approaches. Up to now, CAR modified T-cell or NK-cell against blastoma has been applied in the clinical trials.

Depending on the most advanced techniques and experienced research team, Creative Biolabs has established an efficient and solid platform for offering customers the best service. As a famous technology services provider, Creative Biolabs has helped our customers design a series of innovative strategies according to their special requirements, which has made us garner a solid reputation globally.

Products against Blastoma-specific antigens

Please note: If you do not find your wanted antigen, please feel free to contact with us. Our highly skilled staff is very glad to help you.

Associated malignancy Target antigen Receptor type Product
Glioblastoma IL13RA2 scFv-CD28-OX40-CD3ζ CAR-T-3-M401-2XZ
EGFRvIII scFv-CD28-41BB-CD3ζ CAR-LC056
IL13Rα2 scFv-CD28-41BB-CD3ζ CAR-LC236
CSPG4 scFv-CD28-CD3ζ CAR-MZ116
IL13Rα2 IL13 mutein E13K-CD28-CD3ζ CAR-MZ238
Hepatoblastoma GPC3 scFv-CD28-OX40-CD3ζ CAR-T-3-L342-2XZ
HBV scFv-CD28-41BB-CD3ζ CAR-T-3-M319-2BZ
ErbB2 VHH-CD28-OX40-CD3ζ CAR-T-3-M550-2XZ
Glypican-3 (GPC3) scFv-CD28-41BB-CD3ζ CAR-LC180
Neuroblastoma GD2 scFv-CD28-41BB-CD3ζ CAR-NK-3-M330-2BZ
CD171 scFv-CD28-41BB-CD3ζ CAR-T-3-M307-2BZ
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.